Isradipine, an antihypertensive drug, is emerging as a potential new treatment for Parkinson’s disease due to promising results of in vitro tests. Until now, it was unclear whether administering the drug in vivo would yield the same benefits — new research shows that it does. If human trials are successful, we could have the first drug that slows down the progression of Parkinson’s disease. Isradipine is a calcium-channel inhibitor used to treat hypertension. Previous studies have found that peo
